Sutro biopharma, inc. (STRO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenues (including amounts from related parties of $2,813 during the three months ended March 31, 2020, and $4,916 during the three months ended March 31, 2019)

41,259

42,736

50,517

46,076

41,255

38,419

0

0

0

-

Total revenue

-

-

-

-

-

-

-

-

-

0

Operating expenses
Research and development

68,051

65,612

63,007

58,752

56,360

54,262

53,144

0

0

0

General and administrative

33,590

32,592

31,471

28,707

24,681

21,380

18,701

0

0

0

Total operating expenses

101,641

98,204

94,478

87,459

81,041

75,642

71,845

0

0

0

Loss from operations

-60,382

-55,468

-43,961

-41,383

-39,786

-37,223

-35,013

0

0

0

Interest income

3,539

4,074

4,397

3,836

2,752

1,616

545

0

0

0

Interest and other income (expense), net

0

-

-

-

0

-

-

-

-

-

Interest and other expense, net

-

-

0

0

-

-

0

0

0

-

Interest expense

-

-

-

-

-

-

-

-

-

0

Other income (expense), net

-

-

-

-

-

-

-

-

-

0

Net loss

-61,089

-55,744

-42,448

-39,773

-37,521

-35,317

-35,242

0

0

0

Net loss per share

-0.84

-0.65

-0.56

-0.60

-0.62

65.05

-21.26

-24.17

-25.75

-3.14

Weighted-average shares used in computing net loss per share

23,197

23,095

22,946

22,926

22,865

21,608

481

477

467

451